Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 19 Nov 2020 | |
COVID-19 | Phase 3 | BR | 19 Nov 2020 | |
COVID-19 | Phase 3 | CA | 19 Nov 2020 | |
COVID-19 | Phase 3 | GB | 19 Nov 2020 |
Phase 1/2 | 128 | (MT-2766 High Dose (3.75 µg)) | csgnecisfy(vvgunmsjwg) = dytusofysj ypbezmgxin (swbhdfrzzr, aspfxvtovd - glgopfvtys) View more | - | 01 May 2023 | ||
Placebo (Placebo) | csgnecisfy(vvgunmsjwg) = hujuthyvgk ypbezmgxin (swbhdfrzzr, jczmxmbtnj - lxpxkkcswp) View more |